Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Blood

Volumn 128, Issue 12, 2016, Pages 1562-1566

  Chen, Robert ^a   Gopal, Ajay K ^b   Smith, Scott E ^c   Ansell, Stephen M ^d   Rosenblatt, Joseph D ^e   Savage, Kerry J ^f   Connors, Joseph M ^f   Engert, Andreas ^g   Larsen, Emily K ^h   Huebner, Dirk ⁱ   Fong, Abraham ^h   Younes, Anas ^j  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h SEATTLE GENETICS INC   (United States)

ⁱ MILLENNIUM PHARMACEUTICALS INC   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; ANTIBODY CONJUGATE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY HODGKIN LYMPHOMA; TREATMENT FAILURE; TREATMENT RESPONSE; CANCER STAGING; MORTALITY; PATHOLOGY; PROGNOSIS; REMISSION; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84988697937     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-02-699850     Document Type: Article

References (18)

1. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281(15):10540-10547.
2. Oflazoglu E, Stone IJ, Gordon KA, et al. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood. 2007;110(13):4370-4372.
3. Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in Mycosis Fungoides and Sezary Syndrome with variable CD30 expression level: A multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750-3758.
4. Müller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2(8):741-755.
5. Gardai SJ, Epp A, Law C-L. Brentuximab vedotin-mediated immunogenic cell death [abstract]. Cancer Res. 2015;75(15 Suppl). Abstract 2469.
6. Li F, Zhang X, Emmerton K, et al. Relationship between in vivo antitumor activity of ADC and payload release in preclinical models [abstract]. Cancer Res. 2014;74(19 Suppl). Abstract 3694.
7. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
8. Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531-2533.
9. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program. 2008;2008:326-333.
10. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279-1287.
11. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005;35(10):943-951.
12. Chen R, Palmer JM, Popplewell L, et al. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol. 2011;90(7):803-808.
13. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455-462.
14. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236-1243.
15. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
16. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7(1):24.
17. Zinzani PL, Sasse S, Radford J, Shonukan O, Bonthapally V. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. Crit Rev Oncol Hematol. 2015;95(3):359-369.
18. Perrot A, Monjanel H, Bouabdallah R, et al; Lymphoma Study Association (LYSA). Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica. 2016;101(4):466-473.